Factors influencing ponatinib CSF concentration
| Variable (n) . | Median CSF ponatinib concentration (IQR), ng/mL . | P value . |
|---|---|---|
| Age | .61 | |
| ≥50 y (6) | 2.06 (0.18-3.68) | |
| <50 y (10) | 0.66 (0.31-4.07) | |
| Sex | .77 | |
| Female (8) | 0.49 (0.11-7.13) | |
| Male (8) | 1.23 (0.58-2.2) | |
| Ponatinib dose | .21 | |
| 15 mg/d (2) | 0.84 (0.67-1) | |
| 30 mg/d (14) | 0.36 (0.11-2.83) | |
| 45 mg/d (6) | 4.48 (1.44-9.14) | |
| History of radiation therapy | .77 | |
| Whole body irradiation (5) | 0.86 (0.22-12.68) | |
| No (11) | 1.61 (0.21-3.34) | |
| Concomitant systemic chemotherapy | .45 | |
| Yes (16) | 1.65 (0.21-5) | |
| No (6) | 0.64 (0.11-1.45) | |
| Concomitant intrathecal chemotherapy | .49 | |
| Yes (11) | 0.66 (0.18-2.18) | |
| No (11) | 2.1 (0.12-4.37) | |
| Active CNS involvement | .11 | |
| Yes (3) | 0.12 (0.11-0.3) | |
| No (19) | 2.06 (0.37-5.64) |
| Variable (n) . | Median CSF ponatinib concentration (IQR), ng/mL . | P value . |
|---|---|---|
| Age | .61 | |
| ≥50 y (6) | 2.06 (0.18-3.68) | |
| <50 y (10) | 0.66 (0.31-4.07) | |
| Sex | .77 | |
| Female (8) | 0.49 (0.11-7.13) | |
| Male (8) | 1.23 (0.58-2.2) | |
| Ponatinib dose | .21 | |
| 15 mg/d (2) | 0.84 (0.67-1) | |
| 30 mg/d (14) | 0.36 (0.11-2.83) | |
| 45 mg/d (6) | 4.48 (1.44-9.14) | |
| History of radiation therapy | .77 | |
| Whole body irradiation (5) | 0.86 (0.22-12.68) | |
| No (11) | 1.61 (0.21-3.34) | |
| Concomitant systemic chemotherapy | .45 | |
| Yes (16) | 1.65 (0.21-5) | |
| No (6) | 0.64 (0.11-1.45) | |
| Concomitant intrathecal chemotherapy | .49 | |
| Yes (11) | 0.66 (0.18-2.18) | |
| No (11) | 2.1 (0.12-4.37) | |
| Active CNS involvement | .11 | |
| Yes (3) | 0.12 (0.11-0.3) | |
| No (19) | 2.06 (0.37-5.64) |